Euroscreen acquires exclusive license from ICOS Corporation

Date Posted: Wednesday, January 08, 2003

Print Email to a friend

Euroscreen s.a. announced it has acquired an exclusive license from ICOS Corporation for key patents relating to the human CCR5 receptor and its role in HIV infection. The ICOS patents U.S. 6,265,184, U.S. 6,268,477 and additional pending patent applications on the CCR5 receptor will be combined with Euroscreen's own CCR5 receptor patents and Euroscreen aims to sublicense the resultant expanded patent portfolio to biotechnology and pharmaceutical partners developing therapeutic drugs that inhibit the CCR5 receptor for commercialization. ICOS and Euroscreen will share the revenues generated from licensing these patents

Further Information: http://www.euroscreen.be/


Related news from our archive

Euroscreen Receives Key US Patent Covering Screening Methods Using Human P2Y11 Purinergic Receptor
The new Euroscreen's US patent protects screening methods to single out compounds that modulate, either up or down, the biological activity of the P2Y11 receptor.

Euroscreen Announces the Completion of Research Agreement with GNF and Novartis
Euroscreen and GNF will be engaged in research focused upon the development of therapeutic antibodies targeting G protein coupled receptors (GPCRs).

Euroscreen and Cephalon Extend their Collaboration for GPCR Drug Discovery
Euroscreen has extended the term of an agreement with Cephalon to collaborate on multiple drug discovery programs through 2009.

Euroscreen Awarded U.S. Patent on Human Nociceptin (ORL1) Receptor
Euroscreen SA has been issued an U.S. patent that covers the use of an important human neurology drug target.

Euroscreen Receives Key US Patent Covering Screening Methods Using Human P2Y11 Purinergic Receptor
The new Euroscreen's US patent protects screening methods to single out compounds that modulate, either up or down, the biological activity of the P2Y11 receptor.

Euroscreen Announces the Completion of Research Agreement with GNF and Novartis
Euroscreen and GNF will be engaged in research focused upon the development of therapeutic antibodies targeting G protein coupled receptors (GPCRs).

Euroscreen and Cephalon Extend their Collaboration for GPCR Drug Discovery
Euroscreen has extended the term of an agreement with Cephalon to collaborate on multiple drug discovery programs through 2009.

Euroscreen Awarded U.S. Patent on Human Nociceptin (ORL1) Receptor
Euroscreen SA has been issued an U.S. patent that covers the use of an important human neurology drug target.

Euroscreen and Medarex Announce License and Research Service Agreement
Medarex intends to use its UltiMAb® technology to create antibodies to targets provided by Euroscreen.

IPK and Euroscreen Form Alliance for GPCR Drug Discovery
This partnership highlights the interest in visual-based screening technologies to identify selective drug candidates.

Aureus Licenses AurSCOPE® GPCR to Euroscreen
Euroscreen will use Aureus Pharma's technology to identify GPCR drug candidates.

Euroscreen issued human nociceptin (ORL1) receptor patent

Euroscreen Acquires Exclusive License from Mount Sinai School of Medicine